Loading clinical trials...
Loading clinical trials...
This was a retrospective non-interventional study evaluating the medical records of patients with neuroendocrine tumor (NET) re-treated with lutetium-177 DOTATATE at a single United States institution...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT05687123 · Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, and more
NCT07165886 · Gastroenteropancreatic Neuroendocrine Tumors
NCT03206060 · Pheochromocytoma, Paraganglioma, and more
NCT05636618 · Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, and more
NCT07536087 · Endoscopic Ultrasound-Guided Radiofrequency Ablation, Pancreatic Neuroendocrine Tumors (pNET), and more
Excel Diagnostics & Nuclear Oncology Center
Houston, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions